These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 39334894)

  • 1. Dysfunction of the NMDA Receptor in the Pathophysiology of Schizophrenia and/or the Pathomechanisms of Treatment-Resistant Schizophrenia.
    Okubo R; Okada M; Motomura E
    Biomolecules; 2024 Sep; 14(9):. PubMed ID: 39334894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
    Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
    Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the simultaneous enhancement of NMDA and dopamine D1 receptor-mediated neurotransmission in the effects of clozapine on phencyclidine-induced acute increases in glutamate levels in the rat medial prefrontal cortex.
    Abekawa T; Ito K; Koyama T
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Dec; 374(3):177-93. PubMed ID: 17103144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
    Pietraszek M
    Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.
    Heresco-Levy U
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1113-23. PubMed ID: 14642971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia.
    Dogra S; Conn PJ
    Mol Pharmacol; 2022 May; 101(5):275-285. PubMed ID: 35246479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
    Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
    Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Therapeutic Targets and Drugs for Schizophrenia Beyond Dopamine D2 Receptor Antagonists.
    Peng A; Chai J; Wu H; Bai B; Yang H; He W; Zhao Y
    Neuropsychiatr Dis Treat; 2024; 20():607-620. PubMed ID: 38525480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Passing the torch: The ascendance of the glutamatergic synapse in the pathophysiology of schizophrenia.
    Coyle JT
    Biochem Pharmacol; 2024 Oct; 228():116376. PubMed ID: 38906225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutamatergic mechanisms in schizophrenia.
    Tsai G; Coyle JT
    Annu Rev Pharmacol Toxicol; 2002; 42():165-79. PubMed ID: 11807169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NMDA pathology and treatment of schizophrenia.
    Chang HJ; Lane HY; Tsai GE
    Curr Pharm Des; 2014; 20(32):5118-26. PubMed ID: 24410561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical but not typical antipsychotic drugs ameliorate phencyclidine-induced emotional memory impairments in mice.
    Adem A; Madjid N; Stiedl O; Bonito-Oliva A; Konradsson-Geuken Å; Holst S; Fisone G; Ögren SO
    Eur Neuropsychopharmacol; 2019 May; 29(5):616-628. PubMed ID: 30910381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NMDA glutamate receptor antagonist MK-801 induces proteome changes in adult human brain slices which are partially counteracted by haloperidol and clozapine.
    de Almeida V; Mendes ND; Zuccoli GS; Reis-de-Oliveira G; Almeida GM; Podolsky-Gondim GG; Neder L; Martins-de-Souza D; Sebollela A
    J Neurochem; 2024 Mar; 168(3):238-250. PubMed ID: 38332572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linking Inflammation, Aberrant Glutamate-Dopamine Interaction, and Post-synaptic Changes: Translational Relevance for Schizophrenia and Antipsychotic Treatment: a Systematic Review.
    de Bartolomeis A; Barone A; Vellucci L; Mazza B; Austin MC; Iasevoli F; Ciccarelli M
    Mol Neurobiol; 2022 Oct; 59(10):6460-6501. PubMed ID: 35963926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutamatergic theories of schizophrenia.
    Javitt DC
    Isr J Psychiatry Relat Sci; 2010; 47(1):4-16. PubMed ID: 20686195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct and indirect modulation of the N-methyl D-aspartate receptor.
    Marino MJ; Conn PJ
    Curr Drug Targets CNS Neurol Disord; 2002 Feb; 1(1):1-16. PubMed ID: 12769631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia.
    de Bartolomeis A; Sarappa C; Magara S; Iasevoli F
    Eur J Pharmacol; 2012 May; 682(1-3):1-11. PubMed ID: 22387855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.
    Horacek J; Bubenikova-Valesova V; Kopecek M; Palenicek T; Dockery C; Mohr P; Höschl C
    CNS Drugs; 2006; 20(5):389-409. PubMed ID: 16696579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [NMDA-type glutamate receptor and schizophrenia].
    Nishikawa T; Ishiwata S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2013 Nov; 33(5-6):217-24. PubMed ID: 25069261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.